↓ Skip to main content

Dove Medical Press

Article Metrics

Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease

Overview of attention for article published in Neuropsychiatric Disease and Treatment, February 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter
3 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
22 Mendeley
Title
Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
Published in
Neuropsychiatric Disease and Treatment, February 2018
DOI 10.2147/ndt.s159636
Pubmed ID
Authors

Jian-wei Chen, Shu-qin Xie

Abstract

Depressive and anxiety symptoms could affect the quality of life and prognostic outcomes in chronic kidney disease (CKD) patients, but only a few studies focus on the interventions to manage or prevent these symptoms in CKD patients. Therefore, this study was conducted to compare the efficacy and acceptability of agomelatine versus paroxetine in treating depressive and anxiety symptoms in CKD patients. CKD stage 2-4 patients with depressive and anxiety symptoms were included. The first patient was randomized in April 2013 and the last clinic visit occurred in March 2017. The included patients were randomly assigned to receive paroxetine 20-40 mg/day or agomelatine 25-50 mg/day. The treatment was continued for 12 weeks. The Hamilton Depression Rating Scale (HDRS) (17-item) and Hamilton Anxiety Rating Scale (HARS) were the primary outcome measures, and the response rate, remission rate, and Activities of Daily Living (ADL) scale were the secondary outcome measures. Meanwhile, the adverse events were recorded during the whole treatment period. At baseline and week 4, both groups had similar average HDRS and HARS scores. But at week 8 and 12, compared to the patients receiving paroxetine, the patients receiving agomelatine had significantly lower average HDRS scores (p=0.002,p=0.001, respectively) and HARS scores (p<0.00001,p<0.00001, respectively). At week 12, the patients receiving agomelatine had a non-significantly lower average ADL score, and non-significantly higher response and remission rates. The adverse events in both groups were mild and transient. These results demonstrated that the agomelatine had some advantages over par-oxetine in treating CKD stage 2-4 patients with depressive and anxiety symptoms, and future studies are needed to further explore its efficacy and acceptability.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 22 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 4 18%
Student > Ph. D. Student 4 18%
Unspecified 3 14%
Student > Master 3 14%
Student > Postgraduate 2 9%
Other 6 27%
Readers by discipline Count As %
Psychology 9 41%
Unspecified 4 18%
Neuroscience 3 14%
Medicine and Dentistry 2 9%
Computer Science 1 5%
Other 3 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2018.
All research outputs
#7,236,971
of 12,538,691 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,057
of 2,126 outputs
Outputs of similar age
#190,341
of 389,449 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#36
of 86 outputs
Altmetric has tracked 12,538,691 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,126 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 389,449 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 86 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.